Ftse Mib
36.049,95
-1,16%
DAX
21.395,45
-1,46%
S&P 500
6.040,53
-0,50%
NASDAQ
19.627,44
-0,28%
Bitcoin
95.927,94
-1,81%
Pepperstone
Advertisement
Registration Strip Icon for discussion Registrati per interagire nei nostri forum attivi per discutere con investitori con idee simili.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Affimed NV (AFMD) Affimed NV (AFMD) Notizie

Affimed NV

AFMD
1,01
0,00 (0,00%)
03 Feb 2025 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
17/12/202412:36EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
17/12/202412:30GLOBEAffimed Reports Positive Clinical Update on..
09/12/202419:30GLOBEAffimed Reports Promising Phase 1 Efficacy and Safety Data..
09/12/202412:30GLOBEAffimed to Host Investor Conference Call Highlighting..
08/12/202418:00GLOBEAffimed Announces Positive Results Demonstrating Safety and..
05/12/202412:30GLOBEAffimed Announces Acimtamig and AlloNK® Combination Granted..
14/11/202413:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
14/11/202412:30GLOBEAffimed Reports Third Quarter 2024 Financial Results &..
12/11/202406:15EDGAR2Form EFFECT - Notice of Effectiveness
08/11/202423:09EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
06/11/202412:30GLOBEAffimed to Report Third Quarter 2024 Financial Results &..
05/11/202415:00GLOBEAffimed Announces Acceptance of Three Abstracts at the 2024..
04/11/202419:08EDGAR2Form F-3 - Registration statement by foreign private issuers
15/10/202412:58EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
11/9/202413:41EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
10/9/202412:30GLOBEAffimed to Present at the Cantor Global Healthcare..
05/9/202412:36EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
05/9/202412:30GLOBEAffimed Reports Second Quarter 2024 Financial Results &..
03/9/202414:03EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
03/9/202413:45GLOBEAffimed Appoints Shawn M. Leland as Chief Executive Officer
29/8/202412:30GLOBEAffimed to Report Second Quarter 2024 Financial Results..
12/6/202413:56EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
12/6/202413:13IHMARKETNEWSU.S. Futures Rise on Fed Decision; Oil Gains on Demand..
12/6/202412:30GLOBEAffimed Reports First Quarter 2024 Financial Results &..
06/6/202423:13EDGAR2Form 6-K/A - Report of foreign issuer [Rules 13a-16 and..
05/6/202412:30GLOBEAffimed to Report First Quarter 2024 Financial Results &..
03/6/202412:04EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
01/6/202419:02GLOBEAffimed Provides Follow-up Data of AFM24 plus Atezolizumab..
29/5/202412:30GLOBEAffimed Receives Fast Track Designation for Combination..
28/5/202412:51EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
28/5/202412:30GLOBEAffimed Announces Annual General Meeting of Shareholders
23/5/202423:22EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
23/5/202423:05GLOBEAffimed Announces Positive Early Efficacy and Progression..
14/5/202416:05GLOBEAffimed Announces Acceptance of an Abstract on Preclinical..
24/4/202410:05GLOBEAffimed Announces Acceptance of AFM24 Clinical Abstract at..
28/3/202411:30GLOBEAffimed Reports 2023 Financial Results and Operational..
21/3/202411:30GLOBEAffimed To Report Full Year 2023 Financial Results &..
11/3/202421:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
06/3/202412:34EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
06/3/202412:30GLOBEAffimed Announces 1-for-10 Reverse Stock Split
Apertura: Min: Max:
Chiusura: 1,01

La tua Cronologia

NASDAQ
AFMD
Affimed NV
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network

Rimuovi gli annunci

Iscriviti per un'esperienza senza pubblicità

Nessuna pubblicità

Prova adesso

Conserva gli annunci